'Scar' tactics: Onlookers weigh phase III data in IPF from Intermune, BI
The implausibility of comparing data with would-be competitors from separate trials did not stop industry wizards from following their 'Inpulsis' and guessing anyway, with the upshot that overall chances seemed to ASCEND for Intermune Inc.'s Esbriet in IPF, over Boehringer Ingelheim GmbH's phase III outcomes with the tyrosine kinase inhibitor nintedanib.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter